(Q34020065)

30 July 2017

1 reference

title

Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma (English)

1 reference

30 July 2017

Mecker G Möller

1

1 reference

30 July 2017

Slawomir Salwa

series ordinal

2

1 reference

30 July 2017

Declan M Soden

series ordinal

3

1 reference

30 July 2017

Gerald C O'Sullivan

series ordinal

4

1 reference

30 July 2017

publication date

1 November 2009

1 reference

Expert Review of Anticancer Therapy

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

11

1 reference

30 July 2017

page(s)

1611-1630

1 reference

Melanoma epidemiology and public health.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Bleomycin-mediated electrochemotherapy of basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

The European approach to in-transit melanoma lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Primary cutaneous melanoma. Prognostic classification of anatomic location.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy: an emerging cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Randomized adjuvant therapy trials in melanoma: surgical and systemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Surgery and radiotherapy in the treatment of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Temozolomide for the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Novel therapeutics for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Fraction size in external beam radiation therapy in the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Analysis of dose fractionation in the palliation of metastases from malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Some factors of importance in the radiation treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Radiation therapy toxicity to the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Spatial and temporal control of gene therapy using ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Vaccine therapy for melanoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Immunotherapy of distant metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

The role of isolated limb perfusion for melanoma confined to the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy in treatment of tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy: aspects of preclinical development and early clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electroporation for drug and gene delivery in the clinic: doctors go electric

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Clinical applications of electrochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy on liver tumours in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

In vivo electroporation for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

In vivo results of a new focal tissue ablation technique: irreversible electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Nanosecond pulsed electric fields cause melanomas to self-destruct

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Plasma membrane voltage changes during nanosecond pulsed electric field exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.129

21 January 2018

Identifiers

DOI

10.1586/ERA.09.129

1 reference

30 July 2017

1 reference